Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Sistema de administración oral de medicamentos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORU20180828001
Publicado:
09/10/2018
Caducidad:
10/10/2019
Resumen:
Una universidad rusa es representante de una tecnología de fabricación de un sistema de administración oral de medicamentos. Este sistema ha sido diseñado para poder combinarse con medicamentos que presentan baja biodisponibilidad oral, lo que significa que casi ninguno de los medicamentos consumidos alcanzan el torrente sanguíneo cuando se administran por vía oral. La composición química basada en chitosán modificado es una matriz multicapa nanoestructurada con funciones de transporte y protectoras simultáneamente. La composición en forma de gel inhibe la destrucción del medicamento transferido bajo la influencia de enzimas proteolíticas del tracto gastrointestinal y es absorbida en la sangre, donde el medicamento se descompone gradualmente y se libera sin dañar el hígado. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de comercialización con asistencia técnica o cooperación en materia de investigación.

Details

Tittle:
Drugs oral administration system
Summary:
A university from Russia represents the manufacturing technology oral administration system of drugs into the blood. The system is designed for use in combination with drugs that have otherwise low oral bioavailability, meaning almost none of the consumed drug reach bloodstream (e.g. insulin). Industrial pharmaceutical companies are sought as potential partners under the commercial agreement with technical assistance and research cooperation agreements.
Description:
The developer of technology is a research institute, which is part of a multidisciplinary university from Russia.
There are a number of drugs with extremely low oral bioavailability. Only insignificant portion of a drug reaches bloodstream when administrated orally. This requires more complex ways of taking the medicine: subcutaneous and intravenous injections. The basis of the developed technology is a unique multicomponent oral administration system of drugs into blood. The chemical composition based on modified chitosan is a nanostructured multi-layered matrix that implements transport and protective functions simultaneously. The composition in gel form inhibits destruction of the medicine it transfers under the influence of proteolytic enzymes of the gastrointestinal tract while absorbing into blood where it gradually decomposes and releases the drug without damaging the liver.
The chemical composition (the drug transport matrix) has been developed at the present moment. The structure obtained has been studied and the possibility of transferring various drugs has been determined. The primary tests on bioavailability of insulin were carried out. Based on the results of preliminary tests of the new drug on small lab animals, bioavailability of insulin with oral administration of the new drug is 20-25%.
First of all, an independent test on bioavailability of the transferred medicines (on large lab animals in particular) and development of the reproducibility of substances are necessary for the further development of the project, after which it is possible to conduct preclinical trials of the drug.
Developers consider joint research and development. In this case, developers take on the task of developing the technology of the required drug. The tasks of conducting bioavailability tests by GMP standards and further preclinical trials remain for the partners.

Under the commercial agreement with technical assistance the developers consider the sale of rights on technology, as there are no sufficient capacities at their disposal to do further research and for develop the product to its final form. Developers are ready to provide any necessary assistance - installation and setup of technology, personnel training etc.
Advantages and Innovations:
The developed system allows partial or complete replacement of injections with an oral pill, which is more convenient and not painful way to administer a drug. The unique chitosan-based multilayered complex protects carried drug from the destructive effect of the acidic environment of the gastric tract and allows it to stick to and penetrate through intestinal walls. Bioavailability of the drug reaches 20% even without the use of capsules that protect against gastric acids.
One of the innovations is the alternation of drug-containing layers and protective layers around the core in the matrix. Innovations concerning the core of the matrix, which allows a complex to be absorbed in the intestine, are currently know-how secrets and cannot be disclosed. The technology of production has the ability to control release time of carried drugs, giving the opportunity for the individual approach to treatment.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how
CommeR Statunts Regarding IPR Status:
The PCT application is being prepared.

Partner sought

Type and Role of Partner Sought:
Pharmaceutical companies are sought for buying of technology rights under the commercial agreement with technical assistance.
Joint research and development with pharmaceutical companies and research centers are considered as well, need the independent tests under EU standards.

Client

Type and Size of Client:
Industry 250-499
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Russian

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas